Please ensure Javascript is enabled for purposes of website accessibility

Why Depomed Inc.'s Shares Soared 23.2% Higher

By Todd Campbell - May 10, 2018 at 5:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company rewarded investors with good news today.

What happened

After updating investors on its restructuring and boosting its full-year guidance, shares of Depomed Inc. (ASRT -0.91%) were up 23.2% on Thursday.

So what

Depomed is in the middle of a restructuring of its business that includes out-licensing its lead drug, Nucynta. In December, Collegium (COLL 6.03%) cut a licensing deal for Nucynta that guarantees Depomed $135 million in annual royalties, paid quarterly in arrears, for four years. If sales exceed $233 million per year, then Collegium Pharmaceutical will also pay Depomed a double-digit royalty on top of the minimum license fee. After four years, Depomed will receive double-digit royalties on all net Nucynta sales.

A rising bar chart overlaid on a monitor displaying stock price quotes.

Image source: Getty Images.

The Collegium agreement became official in January, and as a result the impact of accounting for the agreement more than offset a deceleration in Nucynta revenue during the first quarter. Depomed's product sales were $44.4 million, down from $90.3 million one year ago, however, total revenue was $128.4 million, up from $90.3 million last year, because of $83.8 million in revenue tied to the Collegium deal. Specifically, commercialization rights and services provided to Collegium contributed $28.1 million to revenue and non-cash value assigned to inventory transferred to Collegium contributed $55.7 million to revenue.

Depomed also announced it's in-licensed a new dose of Cambia that it hopes to file for FDA approval next year, and it entered into a co-promotion deal with Allegis Pharmaceuticals for Zipsor, under which Allegis will add 30 sales people to market Zipsor to primary care doctors. Sales of Cambia and Zipsor were $6.4 million and $4.7 million, respectively, in Q1.

Additionally, Depomed improved its net loss guidance for 2018. It previously expected to lose between $72 million and $82 million, but now it expects to only lose between $23 million and $33 million this year.

Now what

Because its an opioid pain medicine, sales of Nucynta have been sliding since doctors are shying away from prescribing opioids due to the risk of abuse. Licensing Nucynta to Collegium provides Depomed with a predictable source of high-margin revenue it can use to refocus itself. 

As part of its strategy, the company's licensed rights to cosyntropin (synthetic ACTH depot), a drug that if approved in the U.S. could compete against the billion dollar rare disease treatment Acthar Gel (ACTH depot), which is owned by Mallinckrodt. Depomed says an FDA filing for approval of cosyntropin should happen by the end of this year.

It's good news that Depomed's making progress on its reorganization, but with an enterprise value of nearly $1 billion, the company's going to need a couple of more wins before I think investors ought to consider owning it.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Depomed, Inc. Stock Quote
Depomed, Inc.
ASRT
$2.73 (-0.91%) $0.03
Collegium Pharmaceutical, Inc. Stock Quote
Collegium Pharmaceutical, Inc.
COLL
$18.30 (6.03%) $1.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
321%
 
S&P 500 Returns
111%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.